Dare Bioscience Inc (DARE) Actualités

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

SAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a...

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt...

Daré Bioscience to Participate in Three November Conferences

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Form 8-K - Current report

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Additional Analyses of Phase 2b Data Conducted in Population of Study Participants with Female Sexual...

Form 8-K - Current report

Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

SAN DIEGO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health...

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...

Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s...